RCAG
LAB icon

Rehmann Capital Advisory Group’s Standard BioTools LAB Stock Holding History

Rehmann Capital Advisory Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-153
Closed -$1K – 2185
2018
Q1 		$1K Buy
+153
New +$1K ﹤0.01% 1885

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Rehmann Capital Advisory Group's LAB Position: Q2 2018 in Review

Rehmann Capital Advisory Group sold out of Standard BioTools (LAB) in Q2 2018, closing a stake of 153 shares — an estimated $1K sold.

Rehmann Capital Advisory Group first reported a position in LAB in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 84 funds tracked by Wall St. Rank hold LAB as of Q2 2018.

  • Rehmann Capital Advisory Group reported no remaining Standard BioTools position as of Q2 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 153 Standard BioTools shares in Q2 2018, an estimated $1K.
  • Rehmann Capital Advisory Group first reported a position in Standard BioTools in Q1 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's Standard BioTools position peaked at $1K in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2018, filed 20 Sep 2018.